Psilocybin program

UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the findings look promising. Published in the Nature Medicine journal, the open-label study outcomes...

Cybin One Steps Away From Complete Dosing Cybin (NYSE: CYBN) completed dosing on five of six participant cohorts in its ongoing Phase 2 trial evaluating proprietary deuterated psilocybin analog CYB003 for the treatment of Major Depressive Disorder (MDD). Much like cohort 4, cohort 5 was...

Canadian clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF)  has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ: JAQC), a Special Purpose Acquisition Company (SPAC) for the creation of a new public company representing the combined...

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.) Published in the journal Nature of Neuropsychopharmacology, the findings show a positive correlation, both...

Clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research (CIHR) operating grants on mental health and Substance Use Disorders (SUDs.)  Co-founder and CEO Benjamin Lightburn...

Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a majority of votes cast. See also: EXCLUSIVE: Daniel Carcillo Explains How Wesana Health Is Using...

Canadian mental healthcare biopharma company Apex Labs, Ltd. received approval for its new US-based supplier of Good Manufacturing Practices (GMP)-compliant psilocybin Active Pharmaceutical Ingredient (API.) The company is currently conducting several large-scale, “...

Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which...

As voter-approved psychedelics legalization and regulation of assisted treatments move forward, ancillary businesses are also starting to pop up. Such is the case of Denver-based Mush Love Genetics, a mushroom spore distributor for microscopy research purposes, which announced it is offering...

A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes. See also: San Francisco: Psychedelics Finally Decriminalized, Here...

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for Treatment-Resistant Depression (TRD).  See also: Numinus CEO Outlines MDMA Assisted...

After Washington Gov. Jay Inslee greenlighted SB 5263 creating a pilot program for psilocybin therapy led by the University of Washington's School of Medicine is preparing to begin treatment on Jan. 1, 2025. Based in Seattle, the mandated clinical trial will recruit...

The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way. Recently, several clinical studies have been set up to assess different kinds of treatment, including LSD microdosing and psilocybin for palliative care and cancer-related distress.  One of...

NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application covering what may be the first new salts, co-crystals and polymorphs of psilocybin in history. CEO Dr. Sam Clark stated the company believes the new forms of psilocybin “will...

This year’s edition of Benzinga’s Psychedelics Capital Conference hosted some of the most knowledgeable panelists and hot-button discussions currently in the space. One of them was a conversation between all-time psychedelics advocate and businessman Psycheceutical’s (OTCMKTS:...